Results 11 to 20 of about 15,173,912 (274)

Identifying the silent deficiency: Severe Factor XI deficiency in an asymptomatic patient with isolated prolonged activated partial thromboplastin time—A case report [PDF]

SAGE Open Medical Case Reports
Assessing a patient with a suspected bleeding disorder is a complex aspect of hematology. Prolonged activated partial thromboplastin time often indicates a coagulation factor deficiency or inhibitor and warrants detailed evaluation. Factor XI deficiency,
Awni Alshurafa, Mahmoud Draidi, Feryal Ibrahim, Shehab F. Mohamed, Mohamed A. Yassin   +4 more
doaj   +2 more sources

Deficiência de factor XI.

Acta Médica Portuguesa, 2007
Factor XI deficiency is a rare bleeding disorder in general population, sometimes it can only become clinically evident when patients develop abnormal bleeding after elective surgery. The authors report a clinical case of a 59 year-old woman who after 10
Pedro Conde, Ana Alegria, Andrade Moniz
doaj   +3 more sources

Inhibition of Factor XI Using RBD4059 [PDF]

JACC: Basic to Translational Science
Summary: Coagulation factor XI (FXI) is an attractive target for novel antithrombotic drugs because of its minor role in hemostasis, which may address the current unmet medical need regarding a powerful anticoagulant with low bleeding risk.
Junshi Liang, MSc, Sofia Nilsson, MSc, Johannes Wikström, PhD, Huiqing Cao, PhD, Shuquan Zheng, PhD, Qian Xu, BSc, Xu Yan, MSc, Sebastian Ueckert, PhD, Qi Sun, MSc, Chun Guo, PhD, Hongyan Zhang, PhD, Zicai Liang, PhD, Shan Gao, PhD, Li-Ming Gan, MD, PhD   +13 more
doaj   +2 more sources

Factor XI as a Therapeutic Target [PDF]

Arteriosclerosis, Thrombosis, and Vascular Biology, 2016
Factor XIa is a plasma serine protease that contributes to thrombin generation primarily through proteolytic activation of factor IX. Traditionally considered part of the intrinsic pathway of coagulation, several lines of evidence now suggest that factor
D. Gailani, A. Gruber
semanticscholar   +3 more sources

Identification and characterization of factor XI autoantibodies in 2 patients with systemic lupus erythematosus: insights into mechanisms of acquired factor XI deficiency [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Factor (F)XI is a zymogen that contributes to thrombin generation through activation of FIX. Patients with a complete absence of FXI are prone to developing alloantibody inhibitors after replacement therapy.
Priyanka Srivastava, Amy Zhou, Christine Fuja, Charles S. Eby, Gail Baxter, Anton Matafonov, Serena Fedorov, Miriam Brown, Michael Pettit, Benjamin F. Tillman, David Gailani, Jeremy W. Jacobs   +11 more
doaj   +2 more sources

Biology of factor XI.

Blood
AbstractUnique among coagulation factors, the coagulation factor XI (FXI) arose through a duplication of the gene KLKB1, which encodes plasma prekallikrein. This evolutionary origin sets FXI apart structurally because it is a homodimer with 2 identical subunits composed of 4 apple and 1 catalytic domain.
Moellmer SA, Puy C, McCarty OJT.
europepmc   +3 more sources

A Systematic Review of Factor XI/XIa Inhibitors Versus Direct Oral Anticoagulants in Patients with Atrial Fibrillation [PDF]

Clinical and Applied Thrombosis/Hemostasis
Background Atrial fibrillation (AF) is a leading cause of stroke, necessitating effective anticoagulation. While direct oral anticoagulants (DOACs) have improved stroke prevention, bleeding risks remain a concern.
Zhengbiao Xue MS, Song Liao MS, Haiye Fan MS, Yu Shen MS, Zhi Nie MS   +4 more
doaj   +2 more sources

Factor XI and Heart Failure. [PDF]

Arterioscler Thromb Vasc Biol
Gailani D.
europepmc   +3 more sources

Factor XI/XIa Inhibition: The Arsenal in Development for a New Therapeutic Target in Cardio- and Cerebrovascular Disease

Journal of Cardiovascular Development and Disease, 2022
Despite major advancements in the development of safer and more effective anticoagulant agents, bleeding complications remain a significant concern in the treatment of thromboembolic diseases. Improvements in our understanding of the coagulation pathways
Juan J. Badimon, Gines Escolar, M. Urooj Zafar   +2 more
doaj   +1 more source

Pharmacology and Clinical Development of Factor XI Inhibitors

Circulation, 2023
Therapeutic anticoagulation is indicated for a variety of circumstances and conditions in several fields of medicine to prevent or treat venous and arterial thromboembolism.
A. Greco, C. Laudani, M. Spagnolo, F. Agnello, D. Faro, S. Finocchiaro, M. Legnazzi, M. S. Mauro, P. M. Mazzone, Giovanni Occhipinti, C. Rochira, Lorenzo Scalia, D. Capodanno   +12 more
semanticscholar   +1 more source